KORU Medical Posts 22% Revenue Growth in Q1 2026, Expands Pharma Collaborations
Event summary
- Q1 2026 revenue grew 22% YoY to $11.8M, with gross profit up 20% to $7.2M.
- Net loss improved 31% to ($0.8)M, with adjusted EBITDA at ($0.01)M.
- Submitted 510(k) application for Freedom Infusion System with Deferoxamine.
- Two non-Ig pharma collaborations advanced to Phase III clinical trials.
- Reiterated 2026 guidance: $47.5M–$50M revenue, 61–63% gross margin.
The big picture
KORU Medical's Q1 2026 results reflect strong momentum in its core markets and expanding pharma services. The company's focus on large-volume subcutaneous infusion solutions aligns with broader trends in home-based and ambulatory care. However, its ability to maintain gross margins amid production cost pressures and tariffs will be critical for long-term profitability.
What we're watching
- Regulatory Progress
- The pace at which the 510(k) application for the Freedom Infusion System with Deferoxamine advances will determine its commercialization timeline.
- Pharma Collaborations
- Whether the two Phase III clinical trials will translate into long-term revenue streams for KORU Medical.
- Market Expansion
- How KORU Medical sustains its 35.2% international revenue growth amid geopolitical and tariff-related challenges.
Related topics